Core Viewpoint - WuXi Biologics (02269) has raised its full-year revenue guidance for 2025 from 12%-15% to 14%-16%, indicating strong growth potential in its financial performance [1] Financial Performance - The company reported a 16.1% year-on-year increase in revenue for the first half of the year, reaching RMB 9.95 billion, with a 20.2% growth in continuing operations revenue [1] - EBITDA increased by 50.5% year-on-year to RMB 4.22 billion, while net profit rose by 54.8% to RMB 2.76 billion [1] - Profit attributable to shareholders grew by 56.0% to RMB 2.34 billion, and adjusted net profit increased by 11.6% to RMB 2.84 billion, with an adjusted net profit margin of 28.5% [1] Project and Order Growth - The company signed 86 new comprehensive projects in the first half of the year, setting a historical record for the same period, bringing the total number of comprehensive projects to 864 [1] - The total value of uncompleted orders reached USD 20.34 billion, with an increase of USD 4.21 billion in uncompleted orders over the past three years, indicating a significant growth in revenue expectations [1] Market Environment - The overall innovation drug investment and financing market is recovering, and active licensing transactions are expected to support the continued growth of WuXi Biologics and other leading CXO companies [1]

此外，上半年新签综合项目86个，创同期历史新高，推高综合项目总数至864个。未完成订单总额达 203.4亿美元，三年内未完成订单总额增长至42.1亿美元，近期收入预期增长可观。 此外，整个创新药投融资市场回暖、授权交易活跃等多重利好因素，也将支撑药明生物等CXO龙头企 业业务持续增长。 智通财经APP获悉，药明生物(02269)在刚刚发布的2025年中期业绩报告中，将其2025年全年收入指引从 12%-15%上调至14%-16%。 公司核心财务数据释放加速增长的积极信号，上半年收益同比增长16.1%至99.5亿元，持续经营业务收 益增长20.2%。公司整体盈利能力继续增强，EBITDA同比增长50.5%至42.2亿元，纯利同比增长54.8% 至人民币27.6亿元，公司拥有人应占纯利增长56.0%至人民币23. 4亿元。经调整纯利同比增长11.6%至人 民币28.4亿元，经调整纯利率达28.5%。 ...